Basic research has shown that ADC drugs can upregulate the expression of PD-L1 and major histocompatibility complex class I (MHC-I) in tumor cells, which play a synergistic mechanism when used in combination with immunotherapy [18]. Here, CD274 is linked to neoplasm.